(Bao Wei Er Xie Ben) is a Sanskrit document unearthed in Xinjiang in the 19th century. The ten drugs, which tasted sweet, and used widely were named as the "jīvanīya class of herbs" (Shi Tian Yao) in this document . It was found that "jīvanīya" tasted sweet, felt cold and was often used in tonic decoction for relieving serious vāta (Feng), with references to the ancient medical book Ayurveda and the modern Ayurvedic pharmacopoeia. "Jīvanīya" was constructed with different dossage forms, such as butter, oil, enema, ointment. It can treat some diseases of consumption of the lungs, epilepsy, consumptive diseases and fever of children in (Bao Wei Er Xie Ben). The theories of "jīvanīya" came from Ayurveda. Compared with the theories of traditional Chinese Medicine, the theory that "jīvanīya" can treat consumptive diseases appears similar to the theories in about "Feng Xiao". The theories of Traditional Indian medicine and Chinese medicine appear resemblant, such as the commonalities in terms of using sweet tonics with liquorice and to treat comsumptive diseases.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3760/cma.j.cn112155-20210319-00043 | DOI Listing |
Animals (Basel)
December 2024
College of Environmental Science and Engineering, Ocean University of China, Qingdao 266100, China.
In this study, the total content of REEs ranged from 1.32 to 67.74 μg/kg, with a predominant presence of light REEs.
View Article and Find Full Text PDFEur J Med Res
January 2025
Department of Ophthalmology, The First Affiliated Hospital of USTC, School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230026, China.
Background: The SARS-CoV-2 Omicron variant, since its initial detection, has rapidly spread across the globe, becoming the dominant strain. It is important to study the immune response of SARS-CoV-2 Omicron variant due to its remarkable ability to escape the majority of existing SARS-CoV-2 neutralizing antibodies. The surge in SARS-CoV-2 Omicron infections among most Chinese residents by the end of 2022 provides a unique opportunity to understand immune system's response to Omicron in populations with limited exposure to prior SARS-CoV-2 variants.
View Article and Find Full Text PDFJ Cancer
January 2025
Department of Pathology, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210000, China.
Clin Rheumatol
January 2025
Department of Rheumatology and Immunology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Lujiang Str 17, Hefei, 230001, Anhui, China.
Objective: To examine the effectiveness and safety of two different B cell activating factor/proliferation-inducing ligand inhibitors, telitacicept and belimumab, in treating patients with active systemic lupus erythematosus (SLE).
Methods: Patients with active SLE who received belimumab (n = 100) or telitacicept (n = 101) from 2019 to 2023 at multiple centers in China were retrospectively collected, and the effectiveness and safety of telitacicept and belimumab was evaluated. The subgroups of lupus nephritis and hematologic abnormalities were analyzed to explore if there were any differences in the efficacy of the two biologics on improving kidney and blood systems.
Nanophotonics
June 2024
Department of Materials Science and Engineering, Rensselaer Polytechnic Institute, Troy, NY, USA.
Exciton-polariton condensates, due to their nonlinear and coherent characteristics, have been employed to construct spin Hamiltonian lattices for potentially studying spin glass, critical dephasing, and even solving optimization problems. Here, we report the room-temperature polariton condensation and polaritonic soft-spin XY Hamiltonian lattices in an organic-inorganic halide perovskite microcavity. This is achieved through the direct integration of high-quality single-crystal samples within the cavity.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!